| P50 | author | María Montero | Q57053551 |
| | Juan Pablo Horcajada | Q39065614 |
| P2093 | author name string | Santiago Grau | |
| | Luisa Sorlí | |
| | Erika Esteve | |
| | Nancy Sandoval | |
| P2860 | cites work | In vitro bactericidal activity of daptomycin against staphylococci | Q43895572 |
| | Prediction of bacteremia using TREAT, a computerized decision-support system | Q44546907 |
| | Daptomycin | Q44768109 |
| | High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 |
| | Daptomycin for the treatment of surgical site infections. | Q45921783 |
| | Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. | Q45936598 |
| | Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). | Q46722690 |
| | Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis | Q46796607 |
| | Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 |
| | Predictive value of blood cultures positive for coagulase-negative staphylococci: implications for patient care and health care quality assurance. | Q51632380 |
| | American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference | Q55879451 |
| | In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains | Q33979251 |
| | Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens | Q33981048 |
| | Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 |
| | Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 |
| | Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers | Q35091557 |
| | High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it. | Q35848781 |
| | Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty | Q36364029 |
| | Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity | Q36478933 |
| | Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia | Q36864626 |
| | Multicenter study of high-dose daptomycin for treatment of enterococcal infections | Q37124177 |
| | A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis | Q37286911 |
| | High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. | Q37335865 |
| | Zoonotic Chlamydophila psittaci infections from a clinical perspective | Q37394176 |
| | Daptomycin: evaluation of a high-dose treatment strategy | Q37872921 |
| | Daptomycin: the role of high-dose and combination therapy for Gram-positive infections | Q38120878 |
| | Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL. | Q38164663 |
| | In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin | Q40088863 |
| | Successful treatment of persistent MRSA bacteremia using high-dose daptomycin combined with rifampicin | Q41738358 |
| | Daptomycin in the treatment of prosthetic joint infection by Enterococcus faecalis: safety and efficacy of high-dose and prolonged therapy. | Q41752168 |
| | Clinical experience with daptomycin use in Spain. Global findings from EU-CORE database | Q42743423 |
| | Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm | Q42845932 |
| | High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis | Q43443557 |
| | The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates | Q43693099 |
| P433 | issue | 7 | |
| P921 | main subject | Barcelona | Q1492 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 1145-1154 | |
| P577 | publication date | 2015-06-29 | |
| P1433 | published in | Future Microbiology | Q15759961 |
| P1476 | title | Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain | |
| P478 | volume | 10 | |